<?xml version="1.0" encoding="iso-8859-1"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>HHS/OIG-Audit--&quot;Review of EPOGEN Reimbursement, (A-01-92-00506)&quot;</title>
<meta name="Keywords" content="Audit Report, HHS Office of Inspector General, Office of Audit Services (OAS), End Stage Renal Disease/Dialysis, Medicare, Centers for Medicare and Medicaid Services (CMS)" />
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" />
</head>




<body>

<!-- Google Tag Manager -->
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-JLFR"
height="0" width="0" style="display:none;visibility:hidden" title="googletagmanager"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({"gtm.start":new Date().getTime(),event:"gtm.js"});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!="dataLayer"?"&l="+l:"";j.async=true;j.src="//www.googletagmanager.com/gtm.js?id="+i+dl;f.parentNode.insertBefore(j,f);})(window,document,"script","dataLayer","GTM-JLFR");</script>
<!-- End Google Tag Manager -->


 


<a href="#content"><img src="/images/skip_pixel.gif" alt="Skip to Content" style="border:0 !important" /></a>
<h2><a name="content"></a><em><!-- #BeginLibraryItem "/Library/top anchor.lbi" --><a name="top" id="top"></a><!-- #EndLibraryItem -->Department
    of Health and Human Services</em></h2>
<h3>Office of Inspector General -- AUDIT </h3>
<h3>&quot;Review of EPOGEN Reimbursement,&quot; (A-01-92-00506) </h3>
<h3>February 1, 1993</h3>
<hr noshade="noshade" />
<h5><a href="19200506.pdf">Complete
    Text of Report </a>is available in PDF format (1.41 MB). Copies can also be obtained by contacting the Office of Public
    Affairs at 202-619-1343.</h5>
<hr noshade="noshade" />
<p><strong>EXECUTIVE SUMMARY:</strong></p>
<p>This final report provides the Health Care Financing Administration (HCFA) with information as to whether changes are
  needed in the Medicare reimbursement methodology and rate for the drug, EPOGEN (EPO), used to treat end stage renal disease
  patients. We have found that changes are needed and have recommended that, in the short run, HCFA consider reducing the
  reimbursement rate not to exceed $10.10 per 1,000 units administered which would result in savings of $27.5 million to
  the Medicare program and $6.9 million to the beneficiaries. For a long-term solution, we have recommended that HCFA enter
  into negotiations with Amgen, the drug manufacturer, to lower the rate and also consider rebates to the Medicare program
  based on the volume of EPO usage. </p>
<!-- #BeginLibraryItem "/Library/bottom.lbi" -->

<!-- #EndLibraryItem --></body>
</html>
